BRPI0410808A - (1s,5s)-3- (5,6-dicloro-3-piridinil)-3,6-diazabiciclo[3.2.0]heptano como um agente analgésico eficaz - Google Patents

(1s,5s)-3- (5,6-dicloro-3-piridinil)-3,6-diazabiciclo[3.2.0]heptano como um agente analgésico eficaz

Info

Publication number
BRPI0410808A
BRPI0410808A BRPI0410808-6A BRPI0410808A BRPI0410808A BR PI0410808 A BRPI0410808 A BR PI0410808A BR PI0410808 A BRPI0410808 A BR PI0410808A BR PI0410808 A BRPI0410808 A BR PI0410808A
Authority
BR
Brazil
Prior art keywords
diazabicyclo
pyridinyl
dichloro
heptane
analgesic agent
Prior art date
Application number
BRPI0410808-6A
Other languages
English (en)
Inventor
Michael J Buckley
Jianguo Ji
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0410808A publication Critical patent/BRPI0410808A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"(1S,5S) -3- (5,6-DICLORO-3-PIRIDINIL) -3,6-DIAZABICICLO ¢3.2.0! HEPTANO COMO UM AGENTE ANALGéSICO EFICAZ". A presente invenção revela 1S,5S) -3- (5,6-dicloro3-piridinil) -3,6-diazabiciclo ¢3.2.0! heptano e seu uso no tratamento da dor e outros distúrbios associados com o receptor nicotínico de acetilcolina.
BRPI0410808-6A 2003-05-27 2004-05-20 (1s,5s)-3- (5,6-dicloro-3-piridinil)-3,6-diazabiciclo[3.2.0]heptano como um agente analgésico eficaz BRPI0410808A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
BRPI0410808A true BRPI0410808A (pt) 2006-06-27

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410808-6A BRPI0410808A (pt) 2003-05-27 2004-05-20 (1s,5s)-3- (5,6-dicloro-3-piridinil)-3,6-diazabiciclo[3.2.0]heptano como um agente analgésico eficaz

Country Status (21)

Country Link
US (1) US20040242641A1 (pt)
EP (1) EP1626973B1 (pt)
JP (1) JP4716999B2 (pt)
KR (2) KR101238281B1 (pt)
CN (1) CN1826344B (pt)
AT (1) ATE485296T1 (pt)
AU (1) AU2004243270B2 (pt)
BR (1) BRPI0410808A (pt)
CA (1) CA2526530C (pt)
CY (1) CY1111946T1 (pt)
DE (1) DE602004029671D1 (pt)
DK (1) DK1626973T3 (pt)
ES (1) ES2352199T3 (pt)
MX (1) MXPA05012738A (pt)
NZ (2) NZ588123A (pt)
PL (1) PL1626973T3 (pt)
PT (1) PT1626973E (pt)
SI (1) SI1626973T1 (pt)
TW (1) TWI332502B (pt)
WO (1) WO2004106342A1 (pt)
ZA (1) ZA200509601B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2491034B1 (en) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011090669A1 (en) * 2010-01-20 2011-07-28 Abbott Laboratories Methods for treating pain
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
EP1175416B1 (en) * 1999-04-26 2003-07-16 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
ES2226844T3 (es) * 1999-05-21 2005-04-01 Abbott Laboratories Aminoazaciclos heterociclicos sustituidos utiles como agentes activos sobre el sistema nervioso central.
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
CN1826344B (zh) 2013-03-06
JP2007500220A (ja) 2007-01-11
WO2004106342A1 (en) 2004-12-09
SI1626973T1 (sl) 2011-01-31
MXPA05012738A (es) 2006-02-22
NZ543615A (en) 2009-04-30
ATE485296T1 (de) 2010-11-15
US20040242641A1 (en) 2004-12-02
DK1626973T3 (da) 2011-01-10
CY1111946T1 (el) 2015-11-04
KR20060015738A (ko) 2006-02-20
EP1626973B1 (en) 2010-10-20
AU2004243270A1 (en) 2004-12-09
KR101238281B1 (ko) 2013-03-04
TW200510420A (en) 2005-03-16
CA2526530A1 (en) 2004-12-09
CA2526530C (en) 2013-01-08
KR20120014235A (ko) 2012-02-16
ZA200509601B (en) 2006-10-25
PL1626973T3 (pl) 2011-04-29
AU2004243270B2 (en) 2009-12-17
TWI332502B (en) 2010-11-01
EP1626973A1 (en) 2006-02-22
PT1626973E (pt) 2010-12-31
CN1826344A (zh) 2006-08-30
NZ588123A (en) 2012-04-27
ES2352199T3 (es) 2011-02-16
JP4716999B2 (ja) 2011-07-06
HK1092135A1 (en) 2007-02-02
DE602004029671D1 (de) 2010-12-02

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
WO2005107726A3 (en) Method for the treatment of back pain
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2002043652A3 (en) Anti-proliferative drugs
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2005049000A3 (en) Treatment of phenylketonurias with bh4
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
WO2002098362A3 (en) Use of rank antagonists to treat cancer
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
SE0000303D0 (sv) Novel compounds
WO2004080273A3 (en) Compositions and methods for diagnosing and treating prostate cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2309 DE 07/04/2015.